The use of aspirin in medicine dates at least as far back as Hippocrates who found analgesic effects for the extract (salicin) of white willow bark.1 Aspirin irreversibly inactivates platelet cyclooxygenase, preventing platelets from synthesizing thromboxane A2, a potent vasoconstrictor and promoter of platelet aggregation. Aspirin also has anti-inflammatory and vasodilatory effects that may be important.
Aspirin use is recommended for the secondary prevention of cardiovascular disease (CVD) in patients with prior CVD because it decreases the risk of CVD events and mortality in clinical trials of men and women with CVD.2 The 2009 meta-analysis by the Antithrombotic Trialists' (ATT) collaboration analyzed individual participant data from 16 secondary prevention trials (17 000 individuals; 3306 CVD events).2 Compared with placebo, aspirin resulted in an approximate 10% relative risk (RR) reduction of CVD mortality and total mortality and an approximate 20% RR reduction of CVD events (absolute risk reduction, 6.7% vs 8.2%), with similar reduction in coronary events and ischemic stroke. Aspirin also increased the RR of gastrointestinal tract (GI) bleeding and hemorrhagic stroke, with the majority of hemorrhagic strokes occurring in patients with a history of ischemic stroke or transient cerebral ischemia. Because ischemic stroke is much more common than hemorrhagic stroke, the absolute benefit was greater than the absolute risk of aspirin, with a net RR reduction of total stroke.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 7
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
Assessing the Strength of Recommendations: The GRADE Approach
Users' Guides to the Medical Literature
Was the Individual Trial or Meta-Analysis Large Enough? Just Check the Confidence Intervals
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.